The optimization of the diagnostic work-up in patients with suspected obstructive lung disease by Visser, F.J. et al.
RESEARCH ARTICLE Open Access
The optimization of the diagnostic work-up in
patients with suspected obstructive lung disease
Frank J Visser1*, Milena JMM van der Vegt1, Gert Jan van der Wilt2, Julius P Janssen1
Abstract
Background: Pulmonary function testing is a key procedure in the work-up of patients who are suspected of
having asthma and chronic obstructive lung disease (COPD). Therein, clinical visits and pulmonary function tests
(PFTs) are the major contributors to the overall financial costs.
The aim of this study was to assess whether a specific diagnostic test protocol contributes to the optimization of
the work-up of patients who are suspected of having asthma and COPD.
Methods: A prospective, single-blind, and randomized controlled study was performed. In the control group (CG),
all of the PFTs that were ordered by the lung specialist were carried out. In the experimental group (EG), specific
PFTs were selected according to our protocol. The primary end point was the total cost of achieving a final
diagnosis.
Results: One hundred and seventy-nine patients were included into this study: 86 in the CG and 93 in the EG. The
mean number of tests to diagnosis was 3.8 in the CG versus 2.9 in the EG (P < 0.001). The mean number of
redundant PFTs before diagnosis was 1.2 in the CG versus 0.08 in the EG (P < 0.001). The number of patients who
required an additional outpatient visit to complete diagnosis was higher in the CG in comparison to the EG (P =
0.02). The mean cost of work-up per diagnosis was €227 in the CG versus €181 in the EG (P < 0.001).
Conclusions: In this group of patients with suspected obstructive lung disease, protocol-driven, PFT-based
selection is more cost-effective than test selection at the discretion of lung physicians.
Background
Diagnosing asthma and COPD is an important part of
the daily practice of pulmonary physicians. Pulmonary
function tests (PFTs) play a key role in the work-up of
obstructive pulmonary diseases [1-3].
No exact figures exist for the annual costs that are
associated with current diagnostic processes, although
they are likely to be substantial.
Finding the optimal diagnostic work-up in patients
with obstructive lung disease is challenging. A physician
who routinely orders most or all PFTs in the work-up
of asthma and COPD patients runs the risk of unneces-
sary testing; however, a physician who orders tests more
sparingly runs the risk of unnecessary outpatient
visits. In view of the high incidence of patients with
obstructive lung diseases, it is important to find the
optimal diagnostic work-up in each of these patients. To
this end, we have developed a diagnostic protocol (Fig-
ure 1) that can be jointly used by physicians and pul-
monary function assistants. In our group, some
physicians already use this diagnostic PFT protocol;
however, some of the physicians order PFTs without fol-
lowing the prescribed diagnostic PFT protocol. Prior to
the beginning of this study, there was no available evi-
dence that demonstrated that protocol-driven PFT
ordering is more efficient than physician-driven test
ordering. Therein, we hypothesize that protocol-driven
test ordering will be more efficient than test ordering
without direction from a diagnostic protocol.
The aim of this study was to assess whether protocol-
driven test ordering reduces the number of redundant
pulmonary function tests, decreases the number of out-
patient visits, and increases the cost effectiveness of
patient work-up in comparison to physician-driven test
ordering.
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Methods
A prospective, randomized, and single-blind trial was
conducted at our outpatient unit.
An institutional review board (IRB) approved this
study. This study was only a formal stratification of the
current practice; hence, informed consent was not
necessary.
Methods
The study participants consisted of consecutive adult
patients who were referred to our respiratory outpatient
clinic and suspected to have asthma or COPD at the
end of the first outpatient visit. None of the patients
had recently (in the preceding three years) been diag-
nosed with asthma or COPD by a pulmonary physician.
Patients were primarily referred by general practitioners;
however, two patients referred themselves to our out-
door department, and three were referred by cardiolo-
gists. We excluded patients who were not able to
adequately complete pulmonary function tests, were
referred to a pulmonary physician because of an abnor-
mal X-ray, needed pre-operative consultations, and have
had an infection of the upper or lower airways or a pos-
sible exacerbation of obstructive airway disease in the
past two months.
In the first visit, the physician takes a medical history,
performs a physical examination, makes a differential
diagnosis, and orders laboratory testing, such as a chest
X-ray. Only patients who were most likely to be diag-
nosed with asthma or COPD were included into this
study. Physicians ordered diagnostic tests as they
deemed appropriate and added the reason for the pul-
monary function testing (e.g. suspected obstructive lung
disease). At the end of the first outpatient visit, nurses
randomized the patients into the control group (work-
up at the discretion of the physician) or the experimen-
tal group (work-up in accordance with the protocol) by
pulling an opaque envelope.
PFT lab assistants were notified of the outcome of the
randomization in order to allow them to perform inves-
tigations as ordered or per protocol.
The PFT- protocol is shown in Figure 1. Therein,
when the forced vital capacity (FVC) is less than normal,
a total lung capacity (TLC) measurement was conducted
in order to exclude restrictive lung disease. When the
patients smoked more than 10 pack years, then their
respective diffusion capacities were measured.
A second physician independently examined the
results for each patient and classified the patients as
follows:
Completely reversible (CR)
(1) An airway obstruction that is completely reversible
(FEV1 reversible by ≥ 9% of the predicted value) to a
normal range after beta-2 agonist and anticholinergic
treatment; patients who received reversibility testing
Figure 1 Pulmonary function protocol for obstructive diseases. Criteria for obstruction, airway responsiveness (PC20 histamine), reversibility,
and steroid tests (see text).
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were tested for both bronchodilators; (2) An airway
obstruction that is completely reversible after 14 days of
30 mg/day of prednisone; and (3) normal PFTs but a
decreased PC20 histamine threshold.
This PFT group supports to the diagnosis of asthma.
Non-reversible obstructive (NRO)
Reduced FEV1 and FEV1/FVC values, which are irrever-
sible after beta-2 agonist and/or anti-cholinergic treat-
ment (an FEV1 increase of < 9% of the predicted value)
and no return to the normal range after 10 days of
30 mg/day of prednisone.
This PFT group supports the diagnosis of COPD.
Partly Reversible Obstructive (PRO)
Reversibility is present, but an airflow limitation persists.
FEV1 increases by ≥ 9% of the predicted normal value
but does not return to a normal range after
bronchodilators.
This PFT group supports the diagnosis of asthma with
persistent airflow limitation or COPD with partly
reversibility.
Normal PFT group
No airflow limitation and a normal PC20 histamine
threshold.
This group does not support the diagnosis of obstruc-
tive lung disease; hence, a different diagnosis must be
considered.
The second physician assessed if the appropriate tests
were conducted according to the diagnostic flow and
decided on the pulmonary function classification. He
assessed the decision about the final diagnosis of the
PFT-referring physician.
The second physician calibrated his findings with the
findings of the PFT-ordering physician only if there
were conflicting findings. In all of these cases, we
achieved a consensus on the final diagnosis.
COPD and asthma were finally diagnosed by the first
physician on the basis of medical history (smoking
behavior, allergies, a family history of asthma, and/or a
pre-existing childhood condition); PFTs and clinical
investigations, such as the eosinophil count; and the
radioallergosorbent (RAST) test.
In the protocol, the criteria for obstruction included
an FEV1 < normal and an FEV1/FVC < normal accord-
ing to Quanjer et al. [4]. Airway hyperresponsiveness
was defined as PC20 histamine < 4 mg/ml [5]. Reversi-
bility was defined as a ≥9% improvement in the FEV1 in
comparison to a predicted normal value [6-8]. Steroid
tests consisted of 30 mg/day of prednisone for 10 days
with the intent of reversing the FEV1 to normal levels,
as advised by the Dutch Committee: diagnosis for
asthma and COPD [7].
Forced vital capacity (FVC), forced expiratory volume
in one second (FEV1), and airway responsiveness (PC20
Histamine) were measured according to ERS criteria [1].
During the follow-up visit, the results of all of the
investigations that were carried out at the discretion of
the physician or according to the protocol were available
to the physician who then decided whether a final diag-
nosis could be made. Follow-up visits and additional
PFTs were scheduled as deemed appropriate.
Redundant PFTs were defined as tests that were not
absolutely necessary to establish a final diagnosis. For
example, a reversible obstructive PFT made the hista-
mine provocation test redundant, whereas a normal flow
volume curve made the reversibility test redundant.
The economic analysis was conducted from a health
care perspective that included only direct medical costs.
Where available, unit cost prices were derived from a
national guideline for the economic analysis of health
care services [9]. In other instances, real cost prices
were calculated on the basis of hospital administration
data (Table 1).
Statistical analysis
The unpaired t test with Welch’s correction was used to
test for the statistical significance of differences between
the two groups. An alpha of 0.05 or less was considered
to be significant. For statistical calculations, we used
GraphPad Prism5 for Microsoft Windows http://www.
graphpad.com.
Results
From a total of 183 patients, 179 patients were included
in this study: 86 patients in the CG and 93 patients in
the EG. Four patients were excluded for the following
reasons: one patient had a malignancy, one patient failed
to follow-up, one patient died within a week of the start
of the study, and the protocol was not followed with
one patient. The second physician calibrated his findings
with the findings of the PFT-ordering physician only if
there were conflicting findings. In all of these cases, we
achieved a consensus on the final diagnosis.
Table 2 summarizes patient characteristics at baseline.
Classification of PFT groups on the basis of PFT results
Table 1 The cost of PFTs and follow-up visits
Tests Cost
Flow volume curve €15,00
Reversibility (bronchus dilators) testing €18,00
TLCO (diffusion capacity) €41,00
Hyper reactivity (histamine) €84,00
TLC €41,00
Outpatient visit €41,00
Steroid test €33,00
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and final diagnoses are presented in Table 3. In the
control group, 35 patients were diagnosed with asthma
versus 39 patients in the experimental group. For the
non-reversible obstructive group, these numbers were
eight and nine patients, respectively. For the partly-
reversible obstructive group, these numbers were 12 and
14, respectively.
Diagnosis in the normal PFT group consisted of sar-
coidosis (1), gastroesophageal reflux (GER) (5), rhinitis
and/or sinusitis (7), hyperventilation syndrome (3), per-
sistent cough (15/21 were smokers or ex-smokers), and
dyspnea (3/8 were smokers).
On the basis of clinical assessment, 52 patients were
found to have COPD with the following classifications:
7 patients in GOLD stage 1, 24 patients in stage 2, 13
patients in stage 3, and 8 patients in stage 4.
The total cost of the procedures that were used to
reach a final diagnosis in patients who were suspected
of having obstructive lung diseases.
In the control group, the mean total cost of testing
and outpatient visits per diagnosis were €227.17,
whereas, in the experimental group, this cost was
€180.89 (Figure 2, P < 0.001), which is a 20% reduction
in cost.
The number and cost of outpatient visits until diagnosis
In the control group, two outpatient visits were needed
to reach a final diagnosis in 71 patients, whereas 15
patients needed three outpatient visits (mean 2.17, med-
ian 2). In the experimental group, 90 patients had two
visits, and 3 patients had three visits (mean 2.03, median
2). The difference in total visits between these groups
was statistically significant (P = 0.02). Mean costs were
€88.80 in the control group and €83.00 in the experi-
mental group (Figure 2, P = 0.02).
The number and cost of the PFTs that were needed
for diagnosis:
In the control group, a mean number of 3.81 PFTs per
patient was necessary in order to diagnose asthma or
COPD. In the experimental group, a mean number of
2.94 tests was necessary (Figure 2, P < 0.001). In the
control and experimental groups, the mean costs of
PFTs were €138.37 and €97.89, respectively (P < 0.001).
The number and cost of the redundant PFTs that were
used for diagnosis
In the control group, a mean of 1.20 redundant PFTs
per patient were performed. In the experimental group,
a mean of 0.08 unnecessary PFTs were performed (P <
0.001). The mean costs of redundant tests for diagnoses
in the control and experimental groups were €51.35 and
€3.30, respectively (Figure 2).
Histamine provocation tests and the added cost of
reversibility testing were the two most important
sources of redundant costs (Table 4).
Time until final diagnosis
In the control group, a mean number of 33.02 days was
necessary to reach a final diagnosis, whereas in the
experimental group, a mean number of 35.94 days was
needed (P = 0.51).
Post-hoc
We evaluated the added value in making a diagnosis of
asthma using the steroid test in our patients. Conform-
ing to the protocol, we needed 11 steroid tests in the
control group and 10 steroid tests in the experimental
group. Patient diagnoses did not change with the addi-
tion of these steroid tests.
Discussion
The main finding of our study is that the introduction
of a problem-oriented protocol for ordering PFTs in
patients with suspected obstructive pulmonary disease
can reduce the number of redundant PFTs and outpati-
ent visits, which results in a 20% decrease in costs with-
out an increase in time to final diagnosis. Given the
high frequency of PFT usage for the diagnosis of
obstructive lung disease, this observed decrease in cost
Table 2 Patient characteristics
Control group Experimental group
Number of patients 86 93
Avg. age (years) 55.4 56.8
Sex (% male) 45 46
Height 168.4 170.8
FEV1% pred. 77.8 78.0
FVC % pred. 91.3 91.0
Non-smoker 41% 38%
Ex-smoker 20% 23%
Current smoker 33% 29%
Unknown smoker 6% 10%
Table 3 Classification on the basis of PFT results and
final diagnoses
Classification on the basis of PFT Control
group
Experimental
group
Completely reversible obstructive
(CRO)
41% 42%
Non-reversible obstructive (NRO) 17% 17%
Partly reversible obstructive (PRO). 14% 15%
Normal PFT (NO) 27% 26%
Final diagnosis
Asthma 41% 42%
Asthma partly- reversible 5% 1%
COPD non- reversible- 17% 17%
COPD partly- reversible 10% 14%
Other diagnosis 27% 26%
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results in a substantial savings at a population level. In
our practice of 600 patients per year with suspected
obstructive lung disease, protocol-guided test ordering
can lead to an annual cost reduction of €27,768 =
€46.28 per patient. The most important part of these
potential savings is a reduction in the need for reversi-
bility testing when a normal flow volume curve is
obtained and a reduction in the need for the time-
consuming Our lung function protocol is based on
the asthma and COPD guidelines [7] of the Nether-
lands and is within the ERS and ATS standards
[3,4,6,10]. Therefore, many other countries can use
our protocol with slight modifications. Our patients
with asthma and COPD are demographically similar
to other western European countries, the USA, and
Canada. The only difference is that most patients
were referred to us from a family doctor, as is typi-
cally the case in the UK; however, in some other
countries, a family physician may be skipped more
often. Therefore, a minor selection bias is possible;
however, the diagnostic criteria for COPD or asthma
do not depend on the patient’s physician. Of course,
the skills and the tools are different between general
practitioners (GPs) and pulmonary physicians; how-
ever, for this study, we included only the most basal
lung function tests and omitted tests, such as exer-
cise testing. These tests are not always needed to
confirm a diagnosis of asthma or COPD. We believe
that the protocol discussed herein could easily be fol-
lowed by GPs or hospital physician assistants so long
as they have access to these basic tests, thus, leading
to potentially more health-care savings.
As we stated before, some physicians have used the
protocol-driven lung function protocol that we devel-
oped approximately three years prior to this study. The
author of this study and two other physicians have pri-
marily followed the protocol-driven testing strategy.
Two other physicians (one senior and one junior) did
not implement this protocol-driven testing strategy
because they were not convinced of the ability of this
protocol to save time and cost.
We all agreed to perform this study, and the behavior
of these two physicians did change after the completion
of this study.
Trainees stay for four years in our hospital, and, at the
time of the study, we had five trainees in all stages of
their educational processes. We asked our trainees to
order according to a test-protocol rather than at their
own discretion. We advised them that this would be
more efficient.
Figure 2 Mean cost per patient per diagnosis. Redund. = Redundant.
Table 4 Redundant PFTs
Redundant PFT Control group Experimental group
Number (%) Cost in € Number (%) Cost in €
Histamine
provocation test
19 (22) 1596 1 (1) 84
Reversibility testing 30 (35) 540 1 (1) 18
TLC 30 (35) 1230 3 (3) 123
Diffusion capacity
for CO
24 (28) 984 2 (2) 82
Totals 103 (120) 4323 7 (8) 307
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The protocol allows pulmonary function assistants to
work more efficiently, which decreases the frequency
that they need to interrupt the doctor, who will often be
in a consultation. The workflow is based on our national
guideline, which resembles the international guidelines
of the ERS.
Steroid tests would not have added value to the diag-
nostic workflow in our patient group; hence, we
doubted the need for such a test in a routine setting.
After this study, we removed the steroid tests from the
PFT protocol.
The total time in days to diagnosis was not different
between the two groups; however, without waiting lists
for the outpatient department and for PFT’s, we believe
there will be a difference in time between the CG and
the EG that favors the EG.
We want to emphasize that international guidelines
and several national guidelines do not recommend rever-
sibility testing as a means to distinguish asthma from
COPD, other than when lung function returns to normal
limits. We used three pulmonary function groups as an
intermediate; however, the final diagnosis of asthma or
COPD (or both) can only be made when the full clinical
context, in which PFTs are only a part, is considered.
The prediction threshold of 9% is not a commonly
accepted threshold for distinguishing asthma from
COPD. We only use this criterion to distinguish
between the “non-reversible obstructive” and “partly-
reversible obstructive” PFT groups. Internationally, this
is merely one method that can be used to make this dis-
tinction between these subgroups, and no consensus is
available regarding which criterion is the best [6].
A weakness in our study is the potential of a
Hawthorne effect. The knowledge that they were
involved in a trial may have affected the physicians’
behavior (test ordering, making a final diagnosis). The
only way to avoid this problem is to retrospectively con-
duct the study, which would challenge its internal valid-
ity. Therefore, we decided to conduct a random, parallel
design so as to ensure internal validity (equivalence
between groups, minimal likelihood of confounding);
however, to the extent that our study suffered from a
potential Hawthorne effect, this will most likely have
resulted in an under-estimation of the impact of proto-
col-guided test ordering.
In order to minimize the impact of a potential
Hawthorne effect, we discussed all of the results within
our group after the inclusion period. Some doctors wanted
to minimize patient return visits and ordered tests, which
were regarded to be unnecessary during the second visit.
Conclusion
Problem-orientated PFT ordering significantly reduces
the number of PFTs, the total cost, and the number
of outpatient visits in the diagnosis of asthma and
COPD.
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